Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Salvianic Acid A Sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Salvianic Acid A Sodium: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
CSL Vifor Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
CSL Vifor BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
Latest Hotspot
8 min read
Tacere Therapeutics, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Tacere Therapeutics, Inc BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
8 min read
Mercaptamine-pantetheine disulfide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Mercaptamine-pantetheine disulfide: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
MVA.tHIVconsv4 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
MVA.tHIVconsv4: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Selvigaltin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Selvigaltin: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Naperiglipron Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Naperiglipron: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Ganaplacide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Ganaplacide: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tolinapant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Tolinapant: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
mRNA-1215 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
mRNA-1215: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AMT-191 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
AMT-191: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
LBL-019 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
LBL-019: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.